Autolus Therapeutics plc

NasdaqGS:AUTL Stock Report

Market Cap: US$1.1b

Autolus Therapeutics Balance Sheet Health

Financial Health criteria checks 4/6

Autolus Therapeutics has a total shareholder equity of $111.5M and total debt of $170.9M, which brings its debt-to-equity ratio to 153.3%. Its total assets and total liabilities are $375.4M and $263.9M respectively.

Key information

153.3%

Debt to equity ratio

US$170.90m

Debt

Interest coverage ration/a
CashUS$239.57m
EquityUS$111.47m
Total liabilitiesUS$263.91m
Total assetsUS$375.38m

Recent financial health updates

Recent updates

We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Nov 06
We're Hopeful That Autolus Therapeutics (NASDAQ:AUTL) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Jun 26
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Mar 09
We Think Autolus Therapeutics (NASDAQ:AUTL) Can Afford To Drive Business Growth

Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Dec 12
Is Autolus Therapeutics plc (NASDAQ:AUTL) Worth US$1.9 Based On Its Intrinsic Value?

Autolus stock rises as Moderna uses option to license targeting technology for mRNA therapy

Oct 12

Autolus Therapeutics: Overlooked CAR-T Player With Key Catalysts Approaching

Aug 17

Autolus Therapeutics Q2 2022 Earnings Preview

Aug 03

Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

Apr 19
Here's Why We're Not Too Worried About Autolus Therapeutics' (NASDAQ:AUTL) Cash Burn Situation

We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Dec 15
We Think Autolus Therapeutics (NASDAQ:AUTL) Needs To Drive Business Growth Carefully

Autolus: Developing Better CAR-T In Refractory ALL

Jul 20

Reassessing Autolus Therapeutics

May 04

Will Autolus Therapeutics (NASDAQ:AUTL) Spend Its Cash Wisely?

Apr 28
Will Autolus Therapeutics (NASDAQ:AUTL) Spend Its Cash Wisely?

Do Insiders Own Lots Of Shares In Autolus Therapeutics plc (NASDAQ:AUTL)?

Feb 16
Do Insiders Own Lots Of Shares In Autolus Therapeutics plc (NASDAQ:AUTL)?

Financial Position Analysis

Short Term Liabilities: AUTL's short term assets ($275.3M) exceed its short term liabilities ($44.7M).

Long Term Liabilities: AUTL's short term assets ($275.3M) exceed its long term liabilities ($219.2M).


Debt to Equity History and Analysis

Debt Level: AUTL has more cash than its total debt.

Reducing Debt: AUTL's debt to equity ratio has increased from 0% to 153.3% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: AUTL has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if AUTL has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.